Penserra Capital Management LLC Invests $757,000 in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Penserra Capital Management LLC purchased a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 19,600 shares of the specialty pharmaceutical company’s stock, valued at approximately $757,000. Penserra Capital Management LLC owned 0.06% of Collegium Pharmaceutical as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Pacer Advisors Inc. boosted its holdings in Collegium Pharmaceutical by 31.8% during the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock valued at $109,749,000 after acquiring an additional 821,541 shares during the period. Rubric Capital Management LP boosted its holdings in Collegium Pharmaceutical by 27.2% in the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after purchasing an additional 499,473 shares during the period. Assenagon Asset Management S.A. grew its stake in Collegium Pharmaceutical by 411.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock worth $11,661,000 after purchasing an additional 291,286 shares in the last quarter. Victory Capital Management Inc. grew its stake in Collegium Pharmaceutical by 43.6% during the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after purchasing an additional 215,874 shares in the last quarter. Finally, Emerald Advisers LLC increased its holdings in Collegium Pharmaceutical by 27.2% during the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after purchasing an additional 177,129 shares during the period.

Analyst Upgrades and Downgrades

COLL has been the subject of a number of recent research reports. Truist Financial lifted their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. HC Wainwright raised their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. Piper Sandler reaffirmed a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $42.60.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The trade was a 15.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the transaction, the executive vice president now directly owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. This trade represents a 13.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $30.71 on Thursday. Collegium Pharmaceutical, Inc. has a 52-week low of $25.16 and a 52-week high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The stock’s 50-day moving average price is $35.44 and its 200 day moving average price is $34.68. The stock has a market capitalization of $990.40 million, a PE ratio of 13.47 and a beta of 0.95.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.